#United States #New York #Class Action #The Gross Law Firm #Regencell Bioscience

Regencell Bioscience Holdings Shareholder Alert

On June 23, 2026, The Gross Law Firm published a crucial alert for shareholders of Regencell Bioscience Holdings Limited (NASDAQ: RGC). This announcement pertains to a securities class action lawsuit that could significantly impact those who purchased RGC shares during a specific timeframe.

Key Information for Shareholders

The class action covers a period from October 28, 2024, to October 31, 2025. Shareholders who identified with this class period are strongly encouraged to reach out to The Gross Law Firm regarding the possible appointment of a lead plaintiff. Although being named as a lead plaintiff is not mandatory for participation in the case, registering is essential to ensure your voice is heard.

Allegations in the Class Action

The lawsuit alleges serious misconduct on the part of Regencell's leadership. It claims that misleading statements and omissions about the company's vulnerability to market manipulation led to significant financial loss for investors. Specific allegations include claims that Regencell was not only susceptible to market fluctuations but that these vulnerabilities exposed investors to substantial financial risk. Furthermore, the company faced heightened scrutiny from regulatory bodies, which further complicates its ability to stabilize in the market.

Deadlines to Be Aware Of

The deadline to register as a potential lead plaintiff is June 23, 2026. Shareholders should not procrastinate; immediate action can ensure they receive timely updates and information regarding the case's developments. Registration is essential, and interested shareholders can find more details and begin the registration process through this link.

Next Steps for Investors

Once registered, participating shareholders will gain access to portfolio monitoring software, providing ongoing status updates as the case progresses. This tool is designed to keep investors informed and engaged throughout the litigation process. Importantly, there are no costs or obligations for those looking to participate in this case, which adds a layer of accessibility for all affected individuals.

Why Choose The Gross Law Firm?

The Gross Law Firm is recognized nationally for its commitment to investors' rights, focusing particularly on cases involving fraud and deceptive practices. Their mission is to advocate for responsible corporate behavior, making them a trustworthy choice for impacted shareholders. The firm aims to secure justice and recovery for investors who have suffered losses due to misleading corporate conduct. As tantamount to their commitment, they remind potential plaintiffs that prior results do not guarantee similar outcomes, but they do strive to serve clients earnestly.

Contact Information

For shareholders of Regencell Bioscience Holdings looking to explore their options further, The Gross Law Firm can be reached at:
Address: 15 West 38th Street, 12th Floor, New York, NY, 10018
Email: [email protected]
Phone: (646) 453-8903.

Conclusion

The developments surrounding Regencell Bioscience Holdings highlight the need for vigilance among shareholders. With a lawsuit underway and crucial deadlines approaching, now is the time for impacted investors to arm themselves with knowledge and resources that could facilitate their recovery in this troubling situation.